Distinctive gene expression pattern in VH3-21 utilizing B-cell chronic lymphocytic leukemia

Blood

Volumn 106, Issue 2, 2005, Pages 681-689

  Fält, Susann ^a   Merup, Mats ^b   Tobin, Gerard ^b   Thunberg, Ulf ^b   Gahrton, Gösta ^b   Rosenquist, Richard ^b   Wennborg, Anders ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; PROTEIN KINASE;

ALGORITHM; ANALYTIC METHOD; ARTICLE; B CELL LEUKEMIA; CELL CYCLE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; DNA REPLICATION; GENE EXPRESSION REGULATION; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; IMMUNOGLOBULIN VARIABLE REGION; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; UNINDEXED SEQUENCE;

EID: 22144464117     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-10-4073     Document Type: Article

References (47)

1. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840-1847.
2. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1848-1854.
3. Kröber A, Seiler T, Benner A, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood. 2002;100:1410-1416.
4. Oscier DG, Gardiner AC, Mould SJ, et al. Multi-variate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood. 2002;100:1177-1184.
5. Kipps TJ, Tomhave E, Pratt LF, Duffy S, Chen PP, Carson DA. Developmentally restricted immunoglobulin heavy chain variable region gene expressed at high frequency in chronic lymphocytic leukemia. Prac Natl Acad Sci USA. 1989;86:5913-5917.
6. Schroeder HW, Jr., Dighiero G. The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire. Immunol Today. 1994;15:288-294.
7. Johnson TA, Rassenti LZ, Kipps TJ. Ig VH1 genes expressed in B cell chronic lymphocytic leukemia exhibit distinctive molecular features. J Immunol. 1997;158:235-246.
8. Fais F, Ghiotto F, Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and un mutated antigen receptors. J Clin Invest. 1998;102:1515-1525.
9. Rosenquist R, Lindstrom A, Holmberg D, Lindh J, Roos G. V(H) gene family utilization in different B-cell lymphoma subgroups. Eur J Haematol. 1999;62:123-128.
10. Tobin G, Thunberg U, Johnson A, et al. Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood. 2002;99:2262-2264.
11. Tobin G, Thunberg U, Johnson A, et al. Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14gene use and homologous CDR3s: implicating recognition of a common antigen epitope. Blood. 2003;101:4952-4957.
12. Tobin G, Thunberg U, Karlsson K, et al. Subsets with restricted immunoglobulin gene rearrangement features indicate a rote for antigen selection in the development of chronic lymphocytic leukemia. Blood. 2004;104:2879-2885.
13. Widhopf GF, 2nd, Rassenti LZ, Toy TL, Gribben JG, Wierda WG, Kipps TJ. Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins. Blood. 2004:104:2499-2504.
14. Kröber A, Benner A, Bühler A, Döhner H, Stilgenbauer S. Multivariate Survival Analysis of Specific VH-Genes in CLL: V3-21 and V3-23 Are Prognostic Factors Independently of the VH Mutation Status. ASH. 2002;100.
15. Lin K, Manocha S, Harris RJ, Matrai Z, Sherrington PD, Pettitt AR. High frequency of p53 dysfunction and low level of VH mutation in chronic lymphocytic leukemia patients using the VH3-21 gene segment. Blood. 2003;102:1145-1146.
16. Tobin G, Soderberg O, Thunberg U, Rosenquist R. V(H)3-21 gene usage in chronic lymphocytic leukemia-characterization of a new subgroup with distinct molecular features and poor survival. Leuk Lymphoma. 2004;45:221-228.
17. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503-511.
18. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999;286:531-537.
19. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002;8:68-74.
20. Klein U, Tu Y, Stolovitzky GA, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med. 2001;194:1625-1638.
21. Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001;194:1639-1647.
22. D'Arena G, Di Renzo N, Brugiatelli M, Vigliotti ML, Keating MJ. Biological and clinical heterogeneity of B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 2003;44:223-228.
23. Matutes E, Owusu-Ankomah K, Morilla R, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia. 1994;8:1640-1645.
24. Li AH, Rosenquist R, Forestier E, et al. Clonal rearrangements in childhood and adult precursor B acute lymphoblastic leukemia: a comparative polymerase chain reaction study using multiple sets of primers. Eur J Haematol. 1999;63:211-218.
25. Affymetrix. GeneChip Expression Analysis Data Analysis Fundamentals. http://www.affymetrix, com/support/index.affx; 2003. Accessed on May 27, 2005.
26. Tamayo P, Slonim D, Mesirov J, et al. Interpreting patterns of gene expression with self-organizing maps: methods and application to hematopoietic differentiation. Proc Natl Acad Sci U S A. 1999; 96:2907-2912.
27. Li C, Wong WH. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci USA. 2001;98:31-36.
28. Zhang B, Schmoyer D, Kirov S, Snoddy J. GOTree Machine (GOTM): a web-based platform for interpreting sets of interesting genes using Gene Ontology hierarchies. BMC Bioinformatics. 2004;5:16.
29. Niiro H, Clark EA. Regulation of B-cell fate by antigen-receptor signals. Nat Rev Immunol. 2002;2:945-956.
30. Urban G, Golden T, Aragon IV, et al. Identification of a functional link for the p53 tumor suppressor protein in dexamethasone-induced growth suppression. J Biol Chem. 2003;278:9747-9753.
31. Yoshida K, Inoue I. Regulation of Geminin and Cdt1 expression by E2F transcription factors. Oncogene. 2004;23:3802-3812.
32. Ring HZ, Vameghi-Meyers V, Wang W, Crabtree GR, Francke U. Five SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin (SMARC) genes are dispersed in the human genome. Genomics. 1998;51:140-143.
33. Hsiao PW, Fryer CJ, Trotter KW, Wang W, Archer TK. BAF60a mediates critical interactions between nuclear receptors and the BRG1 chromatin-remodeling complex for transactivation. Mol Cell Biol. 2003;23:6210-6220.
34. Wang TL, Diaz LA, Jr., Romans K, et al. Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc Natl Acad Sci USA. 2004;101:3089-3094.
35. Takaha N, Hawkins AL, Griffin CA, Isaacs WB, Coffey DS. High mobility group protein I(Y): a candidate architectural protein for chromosomal rearrangements in prostate cancer cells. Cancer Res. 2002;62:647-651.
36. Cramer A, Carles A, Millon R, et al. identification of genes associated with tumorigenesis and metastatic potential of hypopharyngeal cancer by microarray analysis. Oncogene. 2003;23:2484-2496.
37. Ulger C, Toruner GA, Alkan M, et al. Comprehensive genome-wide comparison of DNA and RNA level scan using microarray technology for identification of candidate cancer-related genes in the HL-60 cell line. Cancer Genet Cytogenet. 2003; 147:28-35.
38. Zhang J, Kalkum M, Chait BT, Roeder RG. The N-CoR-HDAC3 nuclear receptor corepressor complex inhibits the JNK pathway through the integral subunit GPS2. Mol Cell. 2002;9:611-623.
39. Hoffman B, Amanullah A, Shafarenko M, Liebermann DA. The proto-oncogene c-myc in hematopoietic development and leukemogenesis. Oncogene. 2002;21:3414-3421.
40. Hirai H, Adachi T, Tsubata T. Involvement of cell cycle progression in survival signaling through CD40 in the B-lymphocyte line WEHI-231. Cell Death Differ. 2004;11:261-269.
41. Tsang FC, Po LS, Leung KM, Lau A, Siu WY, Poon RY. ING1b decreases cell proliferation through p53-dependent and -independent mechanisms. FEBS Lett. 2003;553:277-285.
42. Kameyama K, Huang CL, Liu D, et al. Reduced ING1b gene expression plays an important role in carcinogenesis of non-small cell lung cancer patients. Clin Cancer Res. 2003;9:4926-4934.
43. Nouman GS, Anderson JJ, Wood KM, et al. Loss of nuclear expression of the p33(ING1b) inhibitor of growth protein in childhood acute lymphoblastic leukaemia. J Clin Pathol. 2002;55:596-601.
44. Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature. 1997;390:465-471.
45. Chen L, Widhopf G, Huynh L, et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic iymphocytic leukemia. Blood. 2002;100:4609-4614.
46. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003;348:1764-1775.
47. Wiestner A, Rosenwald A, Barry TS, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood. 2003;101:4944-4951.